文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

结核病治疗的未来保障:药物与耐药检测同步开发的框架

Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development.
PubMed 文献 · Lancet Infect Dis · 2025-10-23

文章指出新型结核药物(如贝达喹啉)耐药的出现威胁新方案长期有效性,而耐药检测工具开发滞后是主要障碍。作者提出将药敏试验开发与结核药物开发同步整合的框架,包括早期耐药谱分析和定义流行病学临界值,并呼吁多方合作以加速检测工具开发。

要点

  • 新型结核药物耐药出现威胁全口服方案的长期有效性。
  • 耐药检测工具开发滞后限制临床决策和监测。
  • 需将药敏试验开发与药物开发同步,并建立多方合作平台。

核心结论

  • 将药敏试验开发与结核药物开发同步整合,可确保耐药检测跟上新药引入速度,从而保护新方案疗效。

研究设计与样本

  • 本文为综述/框架性文章,提出整合药物与药敏试验开发的框架和路线图。

主要发现

  • 对新型结核药物(如贝达喹啉)的耐药快速出现,威胁新方案长期有效性。
  • 耐药检测工具开发延迟是限制临床决策和监测的主要障碍。
  • 框架包括早期耐药谱分析和定义适当的流行病学临界值。

临床怎么用

  • 在引入新型结核药物时同步开发药敏试验,以支持临床决策和耐药监测。
  • 建立药物开发者、诊断制造商、监管机构、研究机构、资助者和政策制定者之间的结构化合作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rapid emergence of resistance to novel tuberculosis drugs, such as bedaquiline, is a key threat to the long-term effectiveness of novel regimens. Given that the introduction of these agents has enabled the introduction of an all-oral regimen for rifampicin-resistant and multidrug-resistant tuberculosis, the rise of resistance underscores the urgent need to safeguard their efficacy and responsible use. A major barrier is the delay in developing reliable tools to detect resistance to novel compounds, which limits clinical decision-making and surveillance efforts. Herein, we outline a framework for integrating the development of drug susceptibility testing alongside tuberculosis drug development, including early stage resistance profiling and defining appropriate epidemiological cutoff values. We highlight key gaps, including the need for structured partnerships between drug developers, diagnostic manufacturers, regulators, research institutions, funders, and policy makers. We propose a roadmap to accelerate drug susceptibility testing and development of new tuberculosis regimens, ensuring that resistance detection maintains pace with the introduction of novel drugs. Establishing collaborative platforms for data sharing, genomic analysis, and diagnostic innovation will help ensure that resistance detection evolves in step with drug development, thereby preserving novel treatments and improving global tuberculosis care.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Saluzzo F, Yerlikaya S, Dorman SE, et al. Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development. Lancet Infect Dis. 2025. PMID: 42223242. doi:10.1016/S1473-3099(25)00547-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。